(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 26.97% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.86%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.07%.
Evolus's revenue in 2026 is $285,823,000.On average, 9 Wall Street analysts forecast EOLS's revenue for 2026 to be $21,833,896,043, with the lowest EOLS revenue forecast at $20,790,945,718, and the highest EOLS revenue forecast at $22,708,314,929. On average, 9 Wall Street analysts forecast EOLS's revenue for 2027 to be $25,777,531,701, with the lowest EOLS revenue forecast at $24,183,613,213, and the highest EOLS revenue forecast at $27,653,416,250.
In 2028, EOLS is forecast to generate $39,562,755,164 in revenue, with the lowest revenue forecast at $32,898,633,171 and the highest revenue forecast at $47,208,896,885.